不同化疗方案联合同步胸部放疗治疗局部晚期非小细胞肺癌的疗效与安全性比较:系统综述与网状Meta分析
本研究通过网状Meta分析比较局部晚期非小细胞肺癌同步胸部放疗时不同化疗方案的疗效与安全性,纳入14项随机对照试验共2975例患者。直接比较显示依托泊苷-顺铂方案在总生存和无进展生存上优于紫杉醇-顺铂/卡铂方案。网状Meta分析中所有方案比较的生存差异均未达统计学显著,基于排名S-1-顺铂可能为最优方案。
要点
- 直接比较显示依托泊苷-顺铂方案在总生存上优于紫杉醇-顺铂/卡铂方案(HR=0.85,95%CI:0.77-0.94)。
- 网状Meta分析中所有方案比较的生存差异均未达统计学显著。
- 基于疗效与安全性排名,S-1-顺铂可能为最优方案,其次为尿嘧啶/替加氟-顺铂和培美曲塞-顺铂/卡铂。
核心结论
- 基于疗效与耐受性,S-1-顺铂可能是局部晚期非小细胞肺癌同步胸部放疗的最优选方案,其次为尿嘧啶/替加氟-顺铂和培美曲塞-顺铂/卡铂。
研究设计与样本
- 系统综述与网状Meta分析,检索PubMed、Embase、Cochrane Library、Web of Science及主要国际科学会议,纳入14项随机对照试验共2975例患者,随机接受十二类治疗。
主要发现
- 直接比较Meta分析显示依托泊苷-顺铂方案在总生存上优于紫杉醇-顺铂/卡铂方案(HR=0.85,95%CI:0.77-0.94)。
- 直接比较Meta分析显示依托泊苷-顺铂方案在无进展生存上优于紫杉醇-顺铂/卡铂方案(HR=0.66,95%CI:0.47-0.95)。
- 网状Meta分析中所有方案比较的生存差异均未达统计学显著。
- 基于总生存排名与获益-风险比,S-1-顺铂因疗效最佳且严重不良事件风险低而可能为最优选方案,尿嘧啶/替加氟-顺铂和培美曲塞-顺铂/卡铂分别排名第二和第三。
- 吉西他滨-顺铂和紫杉醇-顺铂/卡铂+西妥昔单抗因疗效差和耐受性差分别列为最差和次差方案。
关键数值与推荐
- 主要结局为总生存,次要结局为无进展生存和严重不良事件,以风险比或比值比及95%置信区间报告。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步直接头对头研究来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains unknown which is the most preferable regimen used concurrently with thoracic radiation for locally advanced non-small cell lung cancer (NSCLC). We performed a network meta-analysis to address this important issue. METHODS: PubMed, Embase, Cochrane Library, Web of Science and major international scientific meetings were searched for relevant randomized controlled trials (RCTs). Overall survival (OS) data was the primary outcome of interest, and progression-free survival (PFS), and serious adverse events (SAEs) were the secondary outcomes of interests, reported as hazard ratio (HR) or odds ratio (OR) and 95% confidence intervals (CIs). RESULTS: 14 RCTs with a total of 2975 patients randomized to receive twelve categories of treatments were included in the meta-analysis. Direct comparison meta-analysis showed that etoposide-cisplatin (EP) was more effective than paclitaxel-cisplatin/carboplatin (PC) in terms of OS (HR = 0.85, 95% CI: 0.77-0.94) and PFS (HR = 0.66, 95% CI: 0.47-0.95). In network meta-analysis, all regimen comparisons did not produce statistically significant differences in survival. Based on treatment ranking of OS and the benefit-risk ratio, S-1-cisplatin (SP) was likely to be the most preferable regimen for its best efficacy and low risk of causing SAEs. Uracil/tegafur-cisplatin (UP) and pemetrexed-cisplatin/carboplatin (PP) were ranked the second and third respectively. Gemcitabine-cisplatin (GP) and PC + Cetuximab (PC-Cet) appeared to be the worst and second-worst regimens for their poor efficacy and poor tolerability. CONCLUSIONS: Based on efficacy and tolerability, SP is likely to be the most preferable regimen used concurrently with thoracic radiation for locally advanced NSCLC, followed by UP and PP. Further direct head-to-head studies are needed to confirm these findings.
引用
- Liu T, He Z, Dang J, et al. Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis. Radiat Oncol. 2019. PMID: 30925881. doi:10.1186/s13014-019-1239-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。